Descriptive only
Any cancer
Overweight or obesity without diabetes (adults)
longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)
2
Randomized trials
6
Treatments
1,213
Participants
9
Events
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 2 trials. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagOutcome assessment, definition: confounded with design: malignant neoplasms, in trial period 1, not stated 1
- FlagRisk of bias, blinding: confounded with design: double_blind 1, open_label 1
- NoteOutcome assessment, time point: selected time points span 32 to 48 weeks
- NoteData handling, input conversions: arms_combined 4
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05616013 | 48 | safety | not stated | not stated | not stated | not stated | not stated | not stated | open_label | industry | 2022 | adults 18 to 80; BMI 30 or more, or 27 or more with comorbidity; no diabetes (HbA1c below 6.5 percent); weight below 150 kg |
| NCT03856047 | 32 | safety | malignant neoplasms, in trial period | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2019 | age 18 or older; BMI 30 or more, or 27 or more with hypertension or dyslipidemia; no diabetes |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT05616013 | A1 | PLACEBO | 48 | arm, events | 0 / 56 | R0015266:Table 3 | |||
| NCT05616013 | A2+A3 | OTHER_ACTIVE_bimagrumab | 48 | arm, events | 2 / 113 | arms_combined | R0015266:Table 3 | ||
| NCT05616013 | A4+A5 | SEMA_SC | 48 | arm, events | 2 / 113 | arms_combined | R0015266:Table 3 | ||
| NCT05616013 | A6+A7+A8+A9 | BIMASEMA_SC | 48 | arm, events | 0 / 225 | arms_combined | R0015266:Table 3 | ||
| NCT03856047 | A1+A2+A3+A4+A5 | OTHER_ACTIVE_cagrilintide | 32 | arm, events | 3 / 506 | arms_combined | R0017871:Results | ||
| NCT03856047 | A6 | LIRA_SC | 32 | arm, events | 1 / 99 | R0017871:Results | |||
| NCT03856047 | A7 | PLACEBO | 32 | arm, events | 1 / 101 | R0017871:Results |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.